Latest News

Page 23 of 30« First...10...2122232425...30...Last »

September 18, 2013

September is National Guide Dog Month

Posted in: Daily Living, Latest News

By Elle Aldridge Freelance writer and Security & Safety Expert Securitycompanies.com Over the past century, improvements to optical health — specifically blindness, macular degeneration (MD) and other disorders — have evolved tremendously. From public initiatives to medical procedures, advances have come a long way. 
One option for those who suffer from macular degeneration and other
read more »

September 17, 2013

C3 Gene Variant Linked To Macular Degeneration

Posted in: Latest News, Research and Developments

Researchers report that a change in the C3 gene, which plays a role in inflammation and in the body’s immune response, also contributes to macular degeneration. After sequencing DNA from 10 regions of the genome that had been previously linked to AMD in previous genetic studies, the researchers turned up two gene variants: one in the
read more »

September 14, 2013

High Dose Stem Cell Transplant Performed

Posted in: Latest News, Research and Developments

Stem Cells (STEM) has announced the first patient to receive a high dose of one million purified human neural stem cells (HuCNS-SC®) in their Phase 1/2 clinical trial. This followed an independent review by the Data Safety Monitoring Committee, which found no safety issues with proceeding to the high dose. The 16-patient trial is designed to evaluate the
read more »

September 14, 2013

Prevent Blindness America Launches New Online Resource, “Living Well with Low Vision”

Posted in: Latest News

To directly address the needs of those with low vision and their caregivers, Prevent Blindness America has launched a new online resource: “Living Well with Low Vision”. The goal of the new website is to make it as easy as possible for people to educate themselves about loss of vision, to meet the daily challenges
read more »

September 12, 2013

New Stem Cell Eye Treatment Study Beginning

Posted in: Latest News, Research and Developments

(Updated March 12, 2017) MD Stem Cells has announced a new and extensive stem cell study  to determine effectiveness of stem cells in ophthalmic disease. The company has been named collaborator for the new Stem Cell Ophthalmology Treatment Study (SCOTS), being conducted in Florida. Conditions eligible for the new study include retinal diseases such as age-related
read more »

September 5, 2013

Eylea Approved in Europe for CRVO

Posted in: Latest News

Regeneron Pharmaceuticals’ Eylea (aflibercept) treatment for central retinal vein occlusion (CRVO) has been approved by the European Commission. Eylea was approved in the United States for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2011, and for macular edema following CRVO in 2012. The drug has also been approved in Europe, Japan, Australia,
read more »

September 2, 2013

Statin Therapy Lowers Risk of Cataracts

Posted in: Latest News, Research and Developments

by Dan Roberts Statin therapy has been shown to reduce inflammation in the retina, but there has been some concern about cataract development for those who use the drugs. In a press conference at the European Society of Cardiology meeting, Aug 30, 2013, John B. Kostis, MD (UMDNJ-Robert Wood Johnson Medical School, New Brunswick, N.J.)
read more »

August 29, 2013

“As-Needed” Injections Are an Option for Wet AMD

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Two-year results from the recently-completed HARBOR trial showed that some patients with wet AMD fare as well from Lucentis (ranibizumab) injections on an as-needed basis compared to a monthly basis. The original Lucentis trial recommended monthly dosing until the eye stabilized. The follow-up study, however, found that 93% of patients responded well with an average
read more »

August 27, 2013

Lampalizumab Effective in Slowing Progression of Dry AMD

Posted in: Latest News, Research and Developments

Roche Pharmaceutical has announced positive phase II results from their MAHALO phase II study of lampalizumab (aka anti-factor D). The study showed a 20.4 percent reduction in progression of advanced dry macular degeneration (geographic atrophy) at 18 months. Lampalizumab is designed to inhibit Complement Factor D, a protein that is part of the alternative complement
read more »

August 22, 2013

Support Groups Can Improve Quality of Life

Posted in: Daily Living, Latest News, Research and Developments

by Dan Roberts Researchers have found that facilitated patient support groups can significantly improve visual quality of life (VQoL) for visually impaired people. Twenty-nine groups of up to six patients each were recruited for participation in a “peer group emotional support service” facilitated by trained counselors for a period of six months. Their responses to
read more »

Page 23 of 30« First...10...2122232425...30...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann